Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.

about

Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.

Item

http://www.wikidata.org/entity/Q38841850

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Erlotinib and gefitinib respon ...... aring analysis with cetuximab.

@en

type

Item

label

Erlotinib and gefitinib respon ...... aring analysis with cetuximab.

@en

prefLabel

Erlotinib and gefitinib respon ...... aring analysis with cetuximab.

@en

P1476

Erlotinib and gefitinib respon ...... paring analysis with cetuximab

@en

P2093

Alexander C Kübler

http://www.w3.org/2001/XMLSchema#string

Axel Seher

http://www.w3.org/2001/XMLSchema#string

Christian Linz

http://www.w3.org/2001/XMLSchema#string

Grit Mutzbauer

http://www.w3.org/2001/XMLSchema#string

Norbert Neckel

http://www.w3.org/2001/XMLSchema#string

Roman C Brands

http://www.w3.org/2001/XMLSchema#string

P2860

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

EGFR and cancer prognosis.

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

P304

759-769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00784-015-1566-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Urs Müller-richter

S Hartmann

P577

2015-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26297130

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab